GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Debt-to-EBITDA

Anxo Pharmaceutical Co (ROCO:6677) Debt-to-EBITDA : 44.17 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Anxo Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$261.6 Mil. Anxo Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$472.5 Mil. Anxo Pharmaceutical Co's annualized EBITDA for the quarter that ended in Jun. 2024 was NT$16.6 Mil. Anxo Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 44.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Anxo Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

ROCO:6677' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.91   Med: 7.16   Max: 26.97
Current: 9.11

During the past 11 years, the highest Debt-to-EBITDA Ratio of Anxo Pharmaceutical Co was 26.97. The lowest was 3.91. And the median was 7.16.

ROCO:6677's Debt-to-EBITDA is ranked worse than
90.7% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs ROCO:6677: 9.11

Anxo Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for Anxo Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anxo Pharmaceutical Co Debt-to-EBITDA Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.13 6.18 7.93 10.49 6.00

Anxo Pharmaceutical Co Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.31 5.03 7.44 5.45 44.17

Competitive Comparison of Anxo Pharmaceutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anxo Pharmaceutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's Debt-to-EBITDA falls into.



Anxo Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Anxo Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(288.145 + 499.695) / 131.31
=6.00

Anxo Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(261.58 + 472.507) / 16.618
=44.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Anxo Pharmaceutical Co  (ROCO:6677) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Anxo Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Anxo Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co Headlines

No Headlines